Bevacizumab: adverse event reports filed with FDA

54,611

reports as suspect product

0.3% of all reports · about 2,446 a year

6,049

reports, 12 months to June 2026

4,988 in the 12 months before

96.4%

marked serious by the reporter

87.6% across the class

18.8%

record death among outcomes, as reported

10,292 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Bevacizumab reports recording the termmedian drug in vascular endothelial growth factor inhibitor

1. Off label useused for a purpose or in a way not on the label12.1%6,599
2. Diarrhoealoose or frequent stools7.6%4,125
3. Hypertensionhigh blood pressure6.4%3,491
4. Nauseafeeling sick6.1%3,305
5. Fatiguetiredness6.1%3,304
6. Deaththe patient died; cause not stated by this term6%3,271
7. Anaemialow red blood cells5.4%2,971
8. Disease progressionthe disease advanced5.3%2,894
9. Neutropenialow neutrophils, a type of white blood cell5.1%2,777
10. Vomitingbeing sick4.8%2,626
11. Thrombocytopenialow platelets4.1%2,244
12. Pyrexiafever4%2,177
13. Proteinuriaprotein in the urine3.5%1,906
14. Decreased appetitereduced appetite3.2%1,750
15. Neuropathy peripheralnerve damage in hands or feet3%1,651
16. Astheniaweakness or lack of energy2.9%1,570
17. Dyspnoeashortness of breath2.8%1,552
18. Febrile neutropeniafever with low white blood cells2.7%1,485
19. Abdominal painstomach or belly pain2.6%1,446
20. Drug ineffectivethe medicine did not work as expected2.6%1,442
21. Malignant neoplasm progression2.5%1,363
22. Myelosuppression2.4%1,308
23. Pulmonary embolisma blood clot in the lung2.1%1,169
24. Dehydrationdehydration2.1%1,145
25. General physical health deteriorationgeneral decline in health2.1%1,139
26. Pneumonialung infection2.1%1,139
27. Platelet count decreasedlow platelet count2%1,101
28. Rashskin rash2%1,076
29. Constipationconstipation1.9%1,064
30. Intentional product use issuedeliberate use not as intended1.9%1,047

Top 30 of 3,059 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 10 drugs in the vascular endothelial growth factor inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 176,429 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 27% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 54,611 reports.

Drugs most often listed in the same reports

Other products listed in reports where Bevacizumab is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the vascular endothelial growth factor inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Bevacizumab as a suspect or interacting product; reports listing it only as a concomitant medication (5,420) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.